logo
Share SHARE
FONT-SIZE Plus   Neg

Vanda Pharma Acquires Rights To NK-1 Receptor Antagonist From Eli Lilly

Vanda Pharmaceuticals Inc. (VNDA) said it has acquired an exclusive world-wide license from Eli Lilly and Co. (LLY) to develop and commercialize a small molecule neurokinin 1 receptor, or NK-1R, antagonist for all human indications.

As per the terms of the agreement with Eli Lilly, Vanda Pharma will pay an initial license fee of $1 million and will be responsible for all development costs. Eli Lilly is also eligible to get extra payments on the basis of achievement of specified development and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. These milestones include $4 million for pre-NDA approval milestones and up to $95 million for future regulatory approval and sales milestones.

Vanda Pharma stated that in 2012, it plans to initiate and complete the technology transfer activities and further examine the clinical and commercial profile of VLY-686. This strategic evaluation will further inform potential indications for an early development clinical program, noted the company.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Canadian power company Emera has agreed to buy Teco Energy Inc for $27.55 per share in cash as part of efforts to expand into Florida and New Mexico. The announcement sent Teco shares surging 28 percent in after-hours trade on the New York Stock Exchange. Xiaomi Corp., nicknamed the "Apple of China" is planning to launch laptops, a report by Bloomberg said. The Chinese brand has been pausing a direct challenge to major smart phone brands in Asian markets in the recent years. It has planned to win over China, India and Brazil markets those together would account for one third of the worldwide sales. Value-priced fashion apparel and accessories retailer Cato Corp. (CATO) Thursday announced a four percent increase in comparable store sales for August. Sales were for the four week period was up five percent to $67 percent from $63.6 million last year. For the thirty weeks ended August 29, the...
comments powered by Disqus
RELATED NEWS
Trade VNDA now with 
Follow RTT